Drug Database
PH

phenylbutyrate (Luc01 / Luc 01 / Pheburane)

✓ Approved

Duchesnay Inc. · 小分子 · 小分子

什么是 phenylbutyrate?

phenylbutyrate 是一种小分子,由Duchesnay Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Luc01, Luc 01, Pheburane
公司Duchesnay Inc.
药物类别小分子
给药途径Oral (PO)
状态Approved

治疗适应症

phenylbutyrate 针对 4 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Congenital, familial and genetic disordersOrnithine transcarbamoylase deficiency✓ Approved
Congenital, familial and genetic disordersCarbamoyl phosphate synthetase deficiency✓ Approved
Congenital, familial and genetic disordersArgininosuccinate synthetase deficiency✓ Approved
Congenital, familial and genetic disordersUrea cycle disorder✓ Approved

相关研究文献

PubMedEuropean thyroid journal2026-11-18

Phenylbutyrate enhances OATP1C1-mediated thyroxine uptake in astrocytes from Mct8 missense mutant mice.

Helms Meike M, Schlimbach Joana J, Dall Esther E, Schweizer Ulrich U et al.

Monocarboxylate transporter 8 (MCT8) is essential for cellular thyroid hormone (TH) transport, and pathogenic variants cause Allan-Herndon-Dudley syndrome (AHDS). We aimed to investigate how the MCT8P253L point mutation, corresponding to human MCT8P321L, affects cerebral TH metabolism in mice and to evaluate whether the chemical chaperone sodium phenylbutyrate (NaPB) can modulate TH uptake and transporter expression in primary astrocytes, thereby providing insight into potential therapeutic strategies for MCT8 deficiency. Mct8P253L/y mice were analyzed for Dio2 mRNA expression and DIO2 enzyme activity as markers of local TH status. Primary astrocytes from mutant and wild-type mice were used to assess T3 and T4 uptake and TH transporter expression after NaPB treatment, combining 3'-mRNA sequencing and mass spectrometry. Mct8P253L/y mice exhibited markedly increased DIO2 activity, consistent with cerebral hypothyroidism, whereas Dio2 mRNA levels remained unchanged. In primary astrocytes, NaPB did not restore MCT8P253L protein expression or T3 uptake but selectively increased T4 uptake. Mass spectrometry revealed that this effect was mediated by NaPB-induced upregulation of the alternative T4 transporter OATP1C1. Accordingly, T4 uptake was not increased in Oatp1c1-deficient astrocytes. NaPB treatment also elevated Slc16a2 and Slco1c1 transcript levels, although the underlying mechanisms remain to be elucidated. NaPB enhances astrocytic T4 uptake in Mct8P253L/y mice via induction of OATP1C1 independently of MCT8 restoration. While OATP1C1 expression at the adult human blood-brain barrier is limited, NaPB may induce alternative TH transporters in glial or endothelial cells, suggesting potential therapeutic benefit for patients with MCT8 deficiency.

PMID 43049452
阅读全文 →
PubMedJournal of pharmacological sciences2026-11-12

Phenylbutyrate-Derived Nitric Oxide Donor Attenuates Renal Fibrosis through the Extracellular Matrix Degradation Pathway.

Arimura Yoshifumi Y, Beppu Takuro T, Imoto Shuhei S, Tamori Ayano A et al.

Chronic kidney disease (CKD) is a major global health burden for which no curative therapy has been established. Decreased bioavailability of nitric oxide (NO) has been implicated in the pathogenesis and progression of CKD. In this study, we investigated the therapeutic potential of NPB, a novel NO donor independently synthesized by our group, in experimental CKD. In an adenine-induced CKD mouse model, NPB administration suppressed serum creatinine and blood urea nitrogen (BUN) to control levels, and Masson's trichrome staining revealed marked attenuation of renal fibrosis. In cultured renal fibroblasts, NPB significantly inhibited transforming growth factor-β1 (TGF-β1)-induced expression of fibronectin and α-smooth muscle actin (α-SMA). Importantly, OH-PB, a non-NO-donating derivative of NPB, showed no beneficial effects in either the in vivo or in vitro. Notably, NPB significantly reduced fibronectin expression even after fibrosis had been induced by TGF-β1 stimulation, an effect not reproduced by TGF-β receptor antagonists. Mechanistically, NPB had little effect on Smad2/3 phosphorylation, the central signaling cascade downstream of TGF-β. Instead, the anti-fibrotic effect of NPB on established fibronectin expression was partially attenuated by the matrix metalloproteinase (MMP) inhibitor doxycycline. Therefore, NPB is a promising therapeutic candidate for CKD that may act by promoting clearance of accumulated extracellular matrix.

PMID 43020532
阅读全文 →
PubMedScientific reports2026-11-12

Functional characterization and pharmacochaperone rescue of a novel SLC6A1 variant associated with developmental epileptic encephalopathies.

Song Ziang Debbie ZD, DeLeeuw Melissa B MB, Mandelenaki Despoina D, Shen Wangzhen W et al.

Mutations in SLC6A1, encoding the γ-aminobutyric acid (GABA) transporter 1 (GAT-1), are associated with a spectrum of neurodevelopmental disorders, including epilepsy syndromes, intellectual disability (ID), and autism. An important question is whether the impact of these mutations can be predicted at scale using artificial intelligence (AI), and how such predictions correlate with experimental findings. In this study, AI was explored as a predictive tool, not as a replacement for data collected experimentally. We reported clinical presentations including seizures and EEG features, autism related phenotypes and motor skills in a novel variant c.1069G > A (p.Ala357Thr, A357T) in two siblings. We used both AI tools and experimental approaches to characterize this novel mutation in the SLC6A1 gene and compared it with another variant in the same amino acid, c.1070 C > T (p.Ala357Val, A357V). Both AI and experimental approaches indicate that the GAT-1(A357T) and (A357V) mutations destabilize the global protein conformation and have increased localization inside the endoplasmic reticulum (ER). Additionally, the presence of the mutant GAT-1 made the wildtype GAT-1 less mature. Radioactive 3H-labeled GABA uptake assay indicated the mutation drastically reduced the function of the GAT-1(A357T) compared with the wildtype across cell types and pharmacochaperones such as 4-phenylbutyrate rescued the trafficking and function of the mutant GAT-1. Common and differential clinical phenotypes were identified in the siblings carrying the same variant. Mutant GAT-1 caused increased ER retention and impaired the trafficking of wild type GAT-1. PBA treatment rescued the mutant GAT-1 protein expression and GABA uptake function. AI-assisted in silico protein structural modeling and experimental approaches consistently suggest that the A357T and A357V variants destabilize global GAT-1 protein conformation. AI-assisted protein stability predictions provide supportive structural insight but cannot replace experimental assessment of GAT-1 expression and function. The online version contains supplementary material available at https://doi.org/10.1038/s41598-026-72601-z.

PMID 43019163
阅读全文 →
PubMedOrphanet journal of rare diseases2026-11-11

Glycerol phenylbutyrate as an effective chemical chaperone for traffic-defective ABCB4 variants: comparative analysis with 4-phenylbutyrate.

Banet Manon M, Riahi Yosra Y, Gonzales Emmanuel E, Jacquemin Emmanuel E et al.

The ABCB4 transporter is localised at the canalicular membrane of hepatocytes, where it mediates the secretion of phosphatidylcholine into bile. Genetic variations in the ABCB4 gene are responsible for rare cholestatic liver diseases of varying severity, the most severe form being progressive familial intrahepatic cholestasis type 3. Existing treatments do not cure most patients with this disease, who require liver transplantation before adulthood. Consequently, there is a need to develop alternative pharmacological therapies. 4-phenylbutyrate and glycerol phenylbutyrate can partially correct the mistrafficking of endoplasmic reticulum-retained ABCB11 variants, thereby improving the clinical condition of patients with ABCB11 deficiency, but in vitro and in vivo data on ABCB4 are limited. In this study, we tested the ability of these two chemical chaperones to rescue traffic-defective ABCB4 variants in vitro by assessing their effects on subcellular localisation and phospholipid efflux capability, which revealed a greater rescuing capacity of glycerol phenylbutyrate over 4-phenylbutyrate. However, the non-equimolar doses used here preclude a direct comparison of the relative efficacy of the two molecules.

PMID 43010049
阅读全文 →
PubMedBrain structure & function2026-11-10

Phenylbutyrate improves recognition memory and increases dendritic spines in the prefrontal cortex and hippocampus in hypertensive female rats.

Martínez-Vásquez Edwin E, Aguilar-Hernández Leonardo L, de Jesús Gómez-Villalobos Ma M, Baltazar-Gaytan Eduardo E et al.

Hypertension and aging are two major global health challenges. They frequently coexist, presenting with aging-related neuronal alterations which are exacerbated under hypertensive conditions. In the present study, we utilized female, 12-month-old spontaneously hypertensive (SH) rats as a translational animal model of combined hypertension and aging. Phenylbutyrate (PB), a compound with reported anti-inflammatory and neuroprotective properties was evaluated for its effects on recognition memory and dendritic architecture. PB treatment significantly improved both short- and long-term recognition memory, as assessed by the novel object recognition test. At the structural level, PB increased dendritic spine density in the prefrontal cortex (PFC) and in multiple subregions of the dorsal hippocampus, including CA1, CA3, and the dentate gyrus. Moreover, PB selectively enhanced the proportion of mature spine phenotypes, increasing mushroom and bifurcated spines in the PFC and hippocampal subregions examined. Together, these findings indicate that PB mitigates recognition memory decline and preserves dendritic spine density and morphology in cortico-hippocampal circuits in this animal model. Our results support PB as a potential therapeutic strategy for neurocognitive dysfunction associated with the comorbidity of hypertension and aging.

PMID 43004009
阅读全文 →
PubMedFrontiers in cell and developmental biology2026-11-08

Integrated human carotid plaque transcriptomics and macrophage perturbation link BCAP31 to endoplasmic reticulum stress, inflammation, and apoptosis.

Wang Yunlong Y, Lin Bin B, Chen Shanjiang S, Yang Jianjian J et al.

Atherosclerotic plaque progression couples chronic inflammation to dysregulated cell survival, but the cellular context and regulatory role of endoplasmic reticulum (ER)-associated death responses in human carotid disease remain incompletely resolved. We integrated paired bulk transcriptomes from 32 carotid plaque and macroscopically intact tissue pairs, laser-captured macrophages from five ruptured and six stable plaques, whole-plaque transcriptomes from 27 intraplaque-hemorrhage and 16 non-hemorrhage lesions, and single-cell RNA sequencing from three patients with matched atherosclerotic core and proximal adjacent tissue. BCAP31 was evaluated by siRNA-mediated depletion in oxidized low-density lipoprotein (oxLDL)-exposed THP-1-derived macrophages, with PCR, immunofluorescence, ELISA, apoptosis assays, and 4-phenylbutyrate treatment. Paired bulk analysis showed coordinated increases in apoptosis, ferroptosis, pyroptosis, necroptosis, inflammasome, inflammatory-response, and TNF/NF-κB programs. Ruptured plaque macrophages showed increases in ferroptosis, pyroptosis, and necroptosis scores, whereas intraplaque-hemorrhage plaques showed broader activation across all prespecified programs. Patient-level single-cell pseudobulk analysis localized a directionally consistent increase in BCAP31 to macrophages, although the estimate did not remain significant after transcriptome-wide correction in the three-patient dataset. Cross-sectional state ordering placed higher BCAP31 expression toward plaque-enriched HLA-C1QC, APOC1-SPP1-remodeling, and SPP1-lipid-loaded macrophage states, while predicted macrophage-to-vascular-wall SPP1 signaling increased in all three patient pairs. BCAP31 was also increased in paired plaque, rupture-macrophage, and intraplaque-hemorrhage cohorts and belonged to a plaque-associated coexpression module. In macrophages derived from THP-1 cells and treated with oxLDL, BCAP31 knockdown increased ER-stress transcripts, nuclear DDIT3, inflammatory cytokine expression and release, and Annexin V-positive apoptosis. The chemical chaperone 4-phenylbutyrate attenuated these effects. Human plaque transcriptomics and macrophage perturbation support a stress-adaptive role for BCAP31 in ER-stress-associated inflammation and apoptosis. Increased tissue expression and the adverse effects of depletion indicate that plaque-associated upregulation may reflect a compensatory response.

PMID 42997182
阅读全文 →

注册免费账户还可查看另外 1290 篇文献

免费注册查看全部文献 →

了解更多phenylbutyrate